C07H 19/207
The phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound
Official title: the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
C07H19/207 (The phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound) appears on 269 US grants and 322 published applications in this corpus.
Search patents in C07H- Granted patents
- 269
- Published applications
- 322
- Assignees
- 174
- Inventors
- 662
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 3 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 3 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 3 | 0 |
| 1990 | 2 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 6 | 2 |
| 2002 | 2 | 5 |
| 2003 | 1 | 7 |
| 2004 | 5 | 7 |
| 2005 | 6 | 8 |
| 2006 | 6 | 1 |
| 2007 | 2 | 3 |
| 2008 | 3 | 3 |
| 2009 | 5 | 5 |
| 2010 | 2 | 9 |
| 2011 | 2 | 10 |
| 2012 | 5 | 8 |
| 2013 | 8 | 14 |
| 2014 | 9 | 24 |
| 2015 | 16 | 14 |
| 2016 | 11 | 25 |
| 2017 | 11 | 19 |
| 2018 | 11 | 13 |
| 2019 | 19 | 27 |
| 2020 | 24 | 23 |
| 2021 | 18 | 23 |
| 2022 | 9 | 19 |
| 2023 | 18 | 14 |
| 2024 | 16 | 21 |
| 2025 | 10 | 7 |
| 2026 | 5 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Artificial nucleic acid, method for producing same, and use thereof22 Sep 2026US 12,741,983 B2Riken Genesis Co., Ltd.
- Fast deprotecting n-exocyclic amino cyclic hydrocarbon protected groups for nucleoside phosphoramidites21 Jul 2026US 12,686,698 B2Agilent Technologies, Inc.
- Adenosine analog and its use in regulating the circadian clock30 Jun 2026US 12,667,584 B2National Institute of Biological Sciences, Beijing
- Asymmetric auxiliary group24 Mar 2026US 12,583,883 B2Wave Life Sciences Ltd.
- Highly active compounds against COVID-1917 Feb 2026US 12,551,499 B2Atea Pharmaceuticals, Inc.
- Substituted bicyclic heterocycle compounds, compositions, and uses thereof1 Oct 2026US 2026/0294949 A1
- Adenosine analog and its use in regulating the circadian clock1 Oct 2026US 2026/0294952 A1National Institute of Biological Sciences, Beijing
- Mrna cap analog and method for producing same, method for producing mrna, and kit27 Aug 2026US 2026/0250311 A1Yamasa Corporation
- 5'-cyclo-phosphonate modified nucleotides20 Aug 2026US 2026/0242406 A1Arrowhead Pharmaceuticals, Inc.
- Novel small molecule kras inhibitor: drugging undruggable targets for cancer therapeutics23 Jul 2026US 2026/0207648 A1Pillai Universal LLC
Most cited
By later US patents
- Electrochemical hydrogenation of nicotinamide adenine dinucleotide401US 4,526,661 ABASF SE · 1985
- Synthesis of oligonucleotide arrays using photocleavable protecting groups208US 6,022,963 AAffymetrix, Inc. · 2000
- Prodrugs phosphorus-containing compounds200US 6,312,662 B1Metabasis Therapeutics, Inc. · 2001
- Substituted nucleotide analogs84US 8,980,865 B2Alios BioPharma, Inc. · 2015
- Water-soluble rhodamine dyes and conjugates thereof79US 6,191,278 B1PE Corporation · 2001